Rare diseases
Investigational molecules
Locations
Evaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis
GreeceA study of Cesnicabtagene autoleucel compared to a drug combination for patients with relapsed or refractory multiple myeloma
The NetherlandsA Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma
AustriaStudy on the Safety and Effectiveness of Anitocabtagene Autoleucel and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma
SpainStudy on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients
PolandStudy Comparing Lenalidomide, Carfilzomib, and Dexamethasone with Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
FinlandStudy of isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems
GreeceStudy Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma
AustriaStudy comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma
AustriaStudy on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
GermanyStudy on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma
SpainStudy Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
